Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OXGENE
The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
- Contract Research Organization-CRO
- Contract Manufacturing Organization
- Gene Therapy, Cell Therapy
Drug Discovery Tools